首页期刊导航|药学学报(英文版)
期刊信息/Journal information
药学学报(英文版)
药学学报(英文版)

双月刊

药学学报(英文版)/Journal Acta Pharmaceutica Sinica BCSCDCSTPCD北大核心SCI
正式出版
收录年代

    Monoclonal antibodies and aptamers:The future therapeutics for Alzheimer's disease

    Alvaro Barrera-Ocampo
    2795-2814页
    查看更多>>摘要:Alzheimer's disease(AD)is considered the most common and prevalent form of dementia of adult-onset with characteristic progressive impairment in cognition and memory.The cure for AD has not been found yet and the treatments available until recently were only symptomatic.Regardless of multi-disciplinary approaches and efforts made by pharmaceutical companies,it was only in the past two years that new drugs were approved for the treatment of the disease.Amyloid beta(Aβ)immunotherapy is at the core of this therapy,which is one of the most innovative approaches looking to change the course of AD.This technology is based on synthetic peptides or monoclonal antibodies(mAb)to reduce Aβ levels in the brain and slow down the advance of neurodegeneration.Hence,this article reviews the state of the art about AD neuropathogenesis,the traditional pharmacologic treatment,as well as the modem active and passive immunization describing approved drugs,and drug prototypes currently under investigation in different clinical trials.In addition,future perspectives on immunotherapeutic strategies for AD and the rise of the aptamer technology as a non-immunogenic alternative to curb the disease progression are discussed.

    Therapeutic strategies of targeting non-apoptotic regulated cell death(RCD)with small-molecule compounds in cancer

    Xin JinWenke JinLinlin TongJia Zhao...
    2815-2853页
    查看更多>>摘要:Regulated cell death(RCD)is a controlled form of cell death orchestrated by one or more cascading signaling pathways,making it amenable to pharmacological intervention.RCD subroutines can be categorized as apoptotic or non-apoptotic and play essential roles in maintaining homeostasis,facilitating development,and modulating immunity.Accumulating evidence has recently revealed that RCD evasion is frequently the primary cause of tumor survival.Several non-apoptotic RCD subroutines have garnered attention as promising cancer therapies due to their ability to induce tumor regression and prevent relapse,comparable to apoptosis.Moreover,they offer potential solutions for overcoming the acquired resistance of tumors toward apoptotic drugs.With an increasing understanding of the underlying mechanisms governing these non-apoptotic RCD subroutines,a growing number of small-molecule compounds targeting single or multiple pathways have been discovered,providing novel strategies for current cancer therapy.In this review,we comprehensively summarized the current regulatory mechanisms of the emerging non-apoptotic RCD subroutines,mainly including autophagy-dependent cell death,ferroptosis,cuproptosis,disulfidptosis,necroptosis,pyroptosis,alkaliptosis,oxeiptosis,parthanatos,mitochondrial permeability transition(MPT)-driven necrosis,entotic cell death,NETotic cell death,lysosome-dependent cell death,and immunogenic cell death(ICD).Furthermore,we focused on discussing the pharmacological regulatory mechanisms of related small-molecule compounds.In brief,these insightful findings may provide valuable guidance for investigating individual or collaborative targeting approaches towards different RCD subroutines,ultimately driving the discovery of novel small-molecule compounds that target RCD and significantly enhance future cancer therapeutics.

    Single-domain antibodies as therapeutics for solid tumor treatment

    Mingkai WangTianlei YingYanling Wu
    2854-2868页
    查看更多>>摘要:Single-domain antibodies(sdAbs),initially identified in camelids or sharks and commonly referred to as nanobodies or VNARs,have emerged as a promising alternative to conventional therapeutic antibodies.These sdAbs have many superior physicochemical and pharmacological properties,including small size,good solubility and thermostability,easier accessible epitopes,and strong tissue penetration.However,the inherent challenges associated with the animal origin of sdAbs limit their clinical use.In recent years,various innovative humanization technologies,including complementarity-determining re-gion(CDR)grafting or complete engineering of fully human sdAbs,have been developed to mitigate po-tential immunogenicity issues and enhance their compatibility.This review provides a comprehensive exploration of sdAbs,emphasizing their distinctive features and the progress in humanization methodol-ogies.In addition,we provide an overview of the recent progress in developing drugs and therapeutic strategies based on sdAbs and their potential in solid tumor treatment,such as sdAb-drug conjugates,multispecific sdAbs,sdAb-based delivery systems,and sdAb-based cell therapy.

    The emerging role of tranexamic acid and its principal target,plasminogen,in skeletal health

    Weixin XieAntonia DonatShan JiangAnke Baranowsky...
    2869-2884页
    查看更多>>摘要:The worldwide burden of skeletal diseases such as osteoporosis,degenerative joint disease and impaired fracture healing is steadily increasing.Tranexamic acid(TXA),a plasminogen inhibitor and anti-fibrinolytic agent,is used to reduce bleeding with high effectiveness and safety in major surgical procedures.With its widespread clinical application,the effects of TXA beyond anti-fibrinolysis have been noticed and prompted renewed interest in its use.Some clinical trials have characterized the effects of TXA on reducing postoperative infection rates and regulating immune responses in patients undergoing surgery.Also,several animal studies suggest potential therapeutic effects of TXA on skeletal diseases such as osteoporosis and fracture healing.Although a direct effect of TXA on the differentiation and function of bone cells in vitro was shown,few mechanisms of action have been reported.Here,we summarize recent findings of the effects of TXA on skeletal diseases and discuss the underlying plasminogen-dependent and-independent mechanisms related to bone metabolism and the immune response.We furthermore discuss potential novel indications for TXA application as a treatment strategy for skeletal diseases.

    Lipid-nanoparticle-enabled nucleic acid therapeutics for liver disorders

    Porkizhi ArjunanDurga KathirveluGokulnath MahalingamAshish Kumar Goel...
    2885-2900页
    查看更多>>摘要:Inherited genetic disorders of the liver pose a significant public health burden.Liver trans-plantation is often limited by the availability of donor livers and the exorbitant costs of immunosuppres-sive therapy.To overcome these limitations,nucleic acid therapy provides a hopeful alternative that enables gene repair,gene supplementation,and gene silencing with suitable vectors.Though viral vectors are the most efficient and preferred for gene therapy,pre-existing immunity debilitating immune re-sponses limit their use.As a potential alternative,lipid nanoparticle-mediated vectors are being explored to deliver multiple nucleic acid forms,including pDNA,mRNA,siRNA,and proteins.Herein,we discuss the broader applications of lipid nanoparticles,from protein replacement therapy to restoring the disease mechanism through nucleic acid delivery and gene editing,as well as multiple preclinical and clinical studies as a potential alternative to liver transplantation.

    Complications and comorbidities associated with antineoplastic chemotherapy:Rethinking drug design and delivery for anticancer therapy

    Xiaoman MaoShuang WuDandan HuangChong Li...
    2901-2926页
    查看更多>>摘要:Despite the considerable advancements in chemotherapy as a cornerstone modality in cancer treatment,the prevalence of complications and pre-existing diseases is on the rise among cancer patients along with prolonged survival and aging population.The relationships between these disorders and cancer are intricate,bearing significant influence on the survival and quality of life of individuals with cancer and presenting challenges for the prognosis and outcomes of malignancies.Herein,we review the prevailing complications and comorbidities that often accompany chemotherapy and summarize the lessons to learn from inadequate research and management of this scenario,with an emphasis on possible strategies for reducing potential complications and alleviating comorbidities,as well as an overview of current preclin-ical cancer models and practical advice for establishing bio-faithful preclinical models in such complex context.

    In silico off-target profiling for enhanced drug safety assessment

    Jin LiuYike GuiJingxin RaoJingjing Sun...
    2927-2941页
    查看更多>>摘要:Ensuring drug safety in the early stages of drug development is crucial to avoid costly fail-ures in subsequent phases.However,the economic burden associated with detecting drug off-targets and potential side effects through in vitro safety screening and animal testing is substantial.Drug off-target interactions,along with the adverse drug reactions they induce,are significant factors affecting drug safety.To assess the liability of candidate drugs,we developed an artificial intelligence model for the pre-cise prediction of compound off-target interactions,leveraging multi-task graph neural networks.The outcomes of off-target predictions can serve as representations for compounds,enabling the differentia-tion of drugs under various ATC codes and the classification of compound toxicity.Furthermore,the pre-dicted off-target profiles are employed in adverse drug reaction(ADR)enrichment analysis,facilitating the inference of potential ADRs for a drug.Using the withdrawn drug Pergolide as an example,we eluci-date the mechanisms underlying ADRs at the target level,contributing to the exploration of the potential clinical relevance of newly predicted off-target interactions.Overall,our work facilitates the early assess-ment of compound safety/toxicity based on off-target identification,deduces potential ADRs of drugs,and ultimately promotes the secure development of drugs.

    LncRNA ZFPM2-AS1 promotes phyllodes tumor progression by binding to CDC42 and inhibiting STAT1 activation

    Shishi HeGuowei HuangRong LeiRurong Jia...
    2942-2958页
    查看更多>>摘要:Breast phyllodes tumor(PT)is a rare fibroepithelial neoplasm with potential malignant behavior.Long non-coding RNAs(lncRNAs)play multifaceted roles in various cancers,but their involve-ment in breast PT remains largely unexplored.In this study,microarray was leveraged for the first time to investigate the role of lncRNA in PT.We identified lncRNA ZFPM2-AS1 was significantly upregulated in malignant PT,and its overexpression endowed PT with high tumor grade and adverse prognosis.Further-more,we elucidated that ZFPM2-AS1 promotes the proliferation,migration,and invasion of malignant PT in vitro.Targeting ZFPM2-AS1 through nanomaterial-mediated siRNA delivery in patient-derived xenograft(PDX)model could effectively inhibit tumor progression in vivo.Mechanistically,our findings showed that ZFPM2-AS1 is competitively bound to CDC42,inhibiting ACK1 and STAT1 activation,thereby launching the transcription of TNFRSF19.In conclusion,our study provides evidence that ZFPM2-AS1 plays a pivotal role in the pathogenesis of breast PT,and suggests that ZFPM2-AS1 could serve as a prognostic indicator for patients with PT as well as a promising novel therapeutic target.

    KHK-A promotes fructose-dependent colorectal cancer liver metastasis by facilitating the phosphorylation and translocation of PKM2

    Chaofan PengPeng YangDongsheng ZhangChi Jin...
    2959-2976页
    查看更多>>摘要:Excessive fructose diet is closely associated with colorectal cancer(CRC)progression.Nevertheless,fructose's specific function and precise mechanism in colorectal cancer liver metastasis(CRLM)is rarely known.Here,this study reported that the fructose absorbed by primary colorectal cancer could accelerate CRLM,and the expression of KHK-A,not KHK-C,in liver metastasis was higher than in paired primary tumors.Furthermore,KHK-A facilitated fructose-dependent CRLM in vitro and in vivo by phosphorylating PKM2 at Ser37.PKM2 phosphorylated by KHK-A inhibited its tetramer formation and pyruvic acid kinase activity but promoted the nuclear accumulation of PKM2.EMT and aerobic glycolysis activated by nuclear PKM2 enhance CRC cells'migration ability and anoikis resis-tance during CRLM progression.TEPP-46 treatment,targeting the phosphorylation of PKM2,inhibited the pro-metastatic effect of KHK-A.Besides,c-myc activated by nuclear PKM2 promotes alternative splicing of KHK-A,forming a positive feedback loop.

    Disruption of cyclin D1 degradation leads to the development of mantle cell lymphoma

    Ke LuMing ZhangHongyu QinSiyu Shen...
    2977-2991页
    查看更多>>摘要:Cyclin D1 has been recognized as an oncogene due to its abnormal upregulation in different types of cancers.Here,we demonstrated that cyclin D1 is SUMOylated,and we identified Itch as a spe-cific E3 ligase recognizing SUMOylated cyclin D1 and mediating SUMO-induced ubiquitination and pro-teasome degradation of cyclin D1.We generated cyclin D1 mutant mice with mutations in the SUMOylation site,phosphorylation site,or both sites of cyclin D1,and found that double mutant mice developed a Mantle cell lymphoma(MCL)-like phenotype.We showed that arsenic trioxide(ATO)en-hances cyclin D1 SUMOylation-mediated degradation through inhibition of cyclin D1 deSUMOylation enzymes,leading to MCL cell apoptosis.Treatment of severe combined immunodeficiency(SCID)mice grafted with MCL cells with ATO resulted in a significant reduction in tumor growth.In this study,we provide novel insights into the mechanisms of MCL tumor development and cyclin D1 regulation and discover a new strategy for MCL treatment.